Our Technology, Pipeline & People
RevImmune’s platform technology is focused on IL-7, which plays a key role in T cell development, expansion, proliferation and mobilization. Importantly, IL-7 plays such a central role in regard to naïve T cells as well as memory T cells.
Our product – CYT107 – is a glycosylated form of IL-7 which is very well tolerated in patients.
A large body of scientific literature documents the central role of IL-7.
CYT107 is currently in multiple Phase 2 clinical trials to treat multiple diseases or conditions, with an additional trial pending.
To date, we have treated over 450 patients with CYT107.
The CYT107 safety profile is excellent: some patients may experience a minor rash, but many do not.
RevImmune's goal is to successfully trial CYT107 on COVID-19 patients as part of a global effort to treat the disease.
Dr. Kenneth Remy
CHIEF SCIENTIFIC OFFICER
Dr. Richard Hotchkiss